Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note released on Wednesday. The firm issued a hold rating on the stock.

Trinity Biotech Trading Down 2.9 %

Shares of TRIB stock opened at $1.32 on Wednesday. The business’s 50 day moving average is $0.93 and its two-hundred day moving average is $1.61. Trinity Biotech has a twelve month low of $0.74 and a twelve month high of $3.55.

Hedge Funds Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its position in shares of Trinity Biotech plc (NASDAQ:TRIB) by 7.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the period. Hunter Associates Investment Management LLC owned approximately 4.72% of Trinity Biotech worth $390,000 as of its most recent SEC filing. 78.97% of the stock is owned by hedge funds and other institutional investors.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.